Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis

Company Overview

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapies that target key mechanisms of cell division. Founded in 1996, the company has built a pipeline of experimental small-molecule inhibitors designed to disrupt the activity of cyclin-dependent kinases (CDKs) and other cell cycle regulators. These targeted agents are intended to selectively halt the proliferation of tumor cells while minimizing effects on healthy tissue.

The company’s most advanced programs include fadraciclib (formerly CYC065), an oral CDK2/9 inhibitor in Phase 1/2 studies for advanced solid tumors and hematologic malignancies, and CYC140, a novel allosteric inhibitor of aurora kinases under early clinical evaluation. Cyclacel’s research and development efforts leverage in-house discovery platforms as well as strategic collaborations with academic institutions and contract research organizations. This collaborative model supports rapid translation of laboratory findings into clinical candidates.

Cyclacel is headquartered in Berkeley Heights, New Jersey, with additional research operations in Dundee, Scotland, reflecting its UK-US footprint. Over the years, the company has advanced multiple compounds into human trials, demonstrating its ability to move promising molecules through preclinical stages. Under its experienced management team, Cyclacel continues to explore combination regimens and biomarker-driven approaches to enhance the therapeutic potential of its pipeline agents for patients with hard-to-treat cancers.

Key Stats

• Today's Range: N/A
• 50-Day Range: $6.36 to $9.28
• 52-Week Range: N/A
• Volume: 220,161 shs
• Average Volume: 82,670 shs
• Market Capitalization: $14.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CYCC Stock Analysis - Frequently Asked Questions

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted its earnings results on Wednesday, August, 13th. The biotechnology company reported ($0.98) EPS for the quarter, topping analysts' consensus estimates of ($72.00) by $71.02.

When did Cyclacel Pharmaceuticals' stock split?

Cyclacel Pharmaceuticals shares reverse split on Monday, July 7th 2025.The 1-15 reverse split was announced on Wednesday, July 2nd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 3rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclacel Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 10/25/2025
• Next Earnings (Estimated): 11/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CYCC
• CIK: 1130166
• Web: www.cyclacel.com
• Phone: (908) 517-7330
• Fax: 866-271-3466
• Employees: 14
• Year Founded: 1992

Profitability

• EPS (Trailing Twelve Months): ($839.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.21 million
• Net Margins: N/A
• Pretax Margin: -54,220.00%
• Return on Equity: -723.64%
• Return on Assets: -145.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.77
• Quick Ratio: 5.77

Sales & Book Value

• Annual Sales: $40 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($58.87) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,240,000
• Free Float: 1,093,000
• Market Cap: $14.43 million
• Optionable: Optionable
• Beta: 0.15